Investigating genetic factors related to COVID-19 vaccine adverse events
Official title: Genomics of COVID-19 Vaccine-induced Adverse Events (Guillain-Barré Syndrome [GBS], Vaccine-induced Immune Thrombotic Thrombocytopenia [VITT]/Thrombosis With Thrombocytopenia Syndrome [TTS], and Myocarditis/Pericarditis)
Run by University of British Columbia · NCT05212792 · Data updated 2026-11-12
This study is trying to find out if certain genes make some people more likely to have serious side effects from COVID-19 vaccines, like Guillain-Barré syndrome or myocarditis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 99 Years |
| Sex | All |
| Enrollment | 6325 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Locations | 1 site (Vancouver, British Columbia) |
| Status | Recruiting |
| Started | June 24, 2022 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT05212792 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals who have received COVID-19 vaccines and developed GBS, VITT/TTS, or myocarditis/pericarditis.
✕Probably not a fit
Patients who have not received a COVID-19 vaccine or those unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify genetic factors that may increase the risk of severe adverse events following COVID-19 vaccination, specifically focusing on conditions such as Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT), and myocarditis/pericarditis. The research will involve a prospective case-control design, comparing individuals who experienced these adverse events with vaccinated controls who did not. Saliva DNA samples will be collected for genomic analysis, including candidate gene studies and genome-wide association studies (GWAS), to uncover potential genetic associations. The study seeks to enhance understanding of the biological mechanisms behind these adverse events to ultimately reduce their occurrence.
Why it matters
Potential benefit: If successful, this study could lead to improved safety measures and personalized approaches to COVID-19 vaccination, minimizing the risk of severe adverse events.
How similar studies have gone: While studies on vaccine adverse events exist, this specific investigation into genetic factors related to COVID-19 vaccine adverse events is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Case: Any patient who received COVID-19 vaccines and developed GBS, VITT/TTS, or myocarditis/pericarditis after vaccination * Control: Any participant who received COVID-19 vaccines and does not experience GBS, VITT/TTS, or myocarditis/pericarditis. Exclusion Criteria: * Individuals who have not received a COVID-19 vaccine * Individuals who are unable to provide informed consent
Where it's running
-
British Columbia Children's Hospital Research Institute
Vancouver, British Columbia, Canada Recruiting
Study contacts
- Principal investigator: Bruce Carleton, PharmD — University of British Columbia
- Study coordinator: Bruce Carleton, PharmD
- Email: bcarleton@popi.ubc.ca
- Phone: 1.877.878.4131
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Monitoring side effects of COVID-19 vaccines worldwide
This study is tracking the side effects of COVID-19 vaccines in healthcare workers, older adults, and schoolteachers to see how common they are and if certain factors affect them.
-
Hepatitis B vaccination for newborns after surgery
This study looks at how safe and effective it is to give hepatitis B vaccinations to newborns who have had surgery, to help find the best timing for these shots.
-
Intradermal Flu Vaccine After All: Watching Immune Response in Skin and Blood
This study tests whether giving the seasonal flu shot into the skin (instead of muscle) changes the immune response in healthy adults, cancer patients about to start immunotherapy, and people with post-acute infection syndromes.
-
Reduced vaccine response to GSK Shingrix in people with SLE
This study tests whether people with systemic lupus erythematosus (SLE) have a different antibody response to the shingles vaccine Shingrix compared with similar people without autoimmune disease.
-
B. Infantis to Boost Immunity in Infants Exposed to HIV
This study is testing if giving a probiotic to infants born to HIV-positive mothers can help boost their immunity and improve their gut health during the first few months of life.
-
Discontinuing anticoagulants after heart surgery for atrial fibrillation
This study is testing if people with atrial fibrillation can safely stop taking blood thinners after having surgery to close a part of their heart, to see if it helps avoid bleeding problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.